Hikma expands impact in Canada with launches of new sterile injectable medicines

London, UK – 9 March 2023 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of four new sterile injectable medicines in Canada, providing important new treatment options for patients and health care providers, and building on the company’s growing presence in the Canadian market.

Press Release Product 9 March 2023

text 1

All of the medicines, which will be launched soon, represent the first or second generic versions of their molecules on the Canadian market and treat conditions across a variety of therapeutic areas – a meaningful expansion in access to medicines for Canadian patients.

The products being launched are:

  • Dantrolene Sodium for Injection, USP, 20 mg Vial
  • Micafungin Sodium for Injection, 50 mg Vial and 100 mg Vial
  • Mitomycin for Injection, USP, 20 mg Vial
  • Progesterone Injection, USP, 50 mg/mL, 10 mL Vial

With these launches, Hikma now markets approximately 30 different sterile injectable medicines in Canada, with plans to launch up to 13 additional sterile injectable products in Canada this year. The company is now a top 10 player in the Canadian generic sterile injectables market[1] and has a leading presence in North America. In the US, Hikma is a top three supplier by volume of generic injectables to US hospitals.[2]

“Since expanding into Canada last year through the acquisition of Teligent’s Canadian injectable assets, we have been working hard to strengthen relationships with customers and Health Canada, while setting the stage to introduce Hikma’s leading sterile injectables portfolio into the country,” said Mike Armstrong, Canada Country Director, Hikma. “The launch of these new sterile injectable medicines is a significant step forward in growing our business in Canada and provides important new treatment options for patients and health care providers.”

“The expansion of our sterile injectable business in Canada continues the strong momentum of our Injectables business globally and builds on our position as a leading supplier of injectable medicines to US hospitals with a reputation for quality and reliability,” said Riad Mishlawi, President, Injectables, Hikma. “We look forward to offering Canadian hospitals critical injectable drugs for their patients’ needs and furthering our impact as a growing player in this important market.”

[1] IQVIA MAT June 2022, excluding biologics, vaccines, and EpiPen

[2] IQVIA MAT December 2022, generic injectable volumes

by eaches, excluding branded generics and Becton Dickinson

These products have been approved for marketing in Canada by Health Canada. These product approvals do not confer the right on Hikma, or any other party, to market these products outside Canada.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.